KYAN Technologies
|
This article is a draft
It is still in development and may change significantly as it is expanded. If you like to contribute to this work, please reach out to the draft's author.
|
 | |
| Status | Active |
|---|---|
| Website | https://kyantechnologies.com/ |
| Vertical(s) | Medtech, Biotechnology |
| Latest Funding Round | Pre-Series A |
| Year founded | 2016 |
| Headquarters | Singapore |
| Technology Readiness Level | Deployment (TRL 7-8) |
KYAN Technologies is a Singapore-based startup that is developing a platform for precision medicine for both treatment and drug development.
Technology
KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy[1] across 20+ different cancer types.
The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models[2].
Traction
List notable customers or partnerships here. Awards should not be listed here, but under "Accolades" instead
Accolades
List awards received by the startup here.
Funding
KYAN Technologies raised US$5 million in pre-Series A funding from lead investor Altara Ventures in October 2022[3].
| Funding History | |
|---|---|
| Investor | Round |
| Altara Ventures | Pre-Series A |
| Seeds Capital | Pre-Series A |
| K3 Ventures | Pre-Series A |
Note: This list is community-maintained and may be incomplete or contain inaccuracies.
See also
- List any other pages directly relevant to KYAN Technologies
References
- ↑ "Optim.AI™ for Clinicians". KYAN Technologies. Retrieved 2025-12-20.
- ↑ "Translational Biobank". KYAN Technologies. Retrieved 2025-12-20.
- ↑ Chong, Jinn Xiung. "Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round".
{{cite web}}: CS1 maint: url-status (link)